{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:43:32Z","timestamp":1793889812260,"version":"4.8.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Migraine is a leading cause of disability worldwide, but it is still underdiagnosed and undertreated. Research on the pathophysiology of this neurological disease led to the discovery that calcitonin gene-related peptide (CGRP) is a key neuropeptide involved in pain signaling during a migraine attack. CGRP-mediated neuronal sensitization and glutamate-based second- and third-order neuronal signaling may be an important component involved in migraine pain. The activation of several serotonergic receptor subtypes can block the release of CGRP, other neuropeptides, and neurotransmitters, and can relieve the symptoms of migraine. Triptans were the first therapeutics developed for the treatment of migraine, working through serotonin 5-HT<jats:sub>1B\/1D<\/jats:sub> receptors. The discovery that the serotonin 1F (5-HT<jats:sub>1F<\/jats:sub>) receptor was expressed in the human trigeminal ganglion suggested that this receptor subtype may have a role in the treatment of migraine. The 5-HT<jats:sub>1F<\/jats:sub> receptor is found on terminals and cell bodies of trigeminal ganglion neurons and can modulate the release of CGRP from these nerves. Unlike 5-HT<jats:sub>1B<\/jats:sub> receptors, the activation of 5-HT<jats:sub>1F<\/jats:sub> receptors does not cause vasoconstriction.<\/jats:p><jats:p>The potency of different serotonergic agonists towards 5-HT<jats:sub>1F<\/jats:sub> was correlated in an animal model of migraine (dural plasma protein extravasation model) leading to the development of lasmiditan. Lasmiditan is a newly approved acute treatment for migraine in the United States and is a lipophilic, highly selective 5-HT<jats:sub>1F<\/jats:sub> agonist that can cross the blood-brain barrier and act at peripheral nervous system (PNS) and central nervous system (CNS) sites.<\/jats:p><jats:p>Lasmiditan activation of CNS-located 5-HT<jats:sub>1F<\/jats:sub> receptors (e.g., in the trigeminal nucleus caudalis) could potentially block the release of CGRP and the neurotransmitter glutamate, thus preventing and possibly reversing the development of central sensitization. Activation of 5-HT<jats:sub>1F<\/jats:sub> receptors in the thalamus can block secondary central sensitization of this region, which is associated with progression of migraine and extracephalic cutaneous allodynia. The 5-HT<jats:sub>1F<\/jats:sub> receptors are also elements of descending pain modulation, presenting another site where lasmiditan may alleviate migraine. There is emerging evidence that mitochondrial dysfunction might be implicated in the pathophysiology of migraine, and that 5-HT<jats:sub>1F<\/jats:sub> receptors can promote mitochondrial biogenesis. While the exact mechanism is unknown, evidence suggests that lasmiditan can alleviate migraine through 5-HT<jats:sub>1F<\/jats:sub> agonist activity that leads to inhibition of neuropeptide and neurotransmitter release and inhibition of PNS trigeminovascular and CNS pain signaling pathways.<\/jats:p>","DOI":"10.1186\/s10194-020-01132-3","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T15:01:31Z","timestamp":1592233291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":143,"title":["Lasmiditan mechanism of action \u2013 review of a selective 5-HT1F agonist"],"prefix":"10.1186","volume":"21","author":[{"given":"David B.","family":"Clemow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Hochstetler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Ossipov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Hake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Blumenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"issue":"11","key":"1132_CR1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2174\/1389557516666160728121050","volume":"17","author":"CM Villalon","year":"2017","unstructured":"Villalon CM, VanDenBrink AM (2017) The role of 5-Hydroxytryptamine in the pathophysiology of migraine and its relevance to the Design of Novel Treatments. Mini Rev Med Chem 17(11):928\u2013938","journal-title":"Mini Rev Med Chem"},{"issue":"10","key":"1132_CR2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","volume":"6","author":"TW Ho","year":"2010","unstructured":"Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6(10):573\u2013582","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1132_CR3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.nurt.2010.02.004","volume":"7","author":"L Edvinsson","year":"2010","unstructured":"Edvinsson L, Ho TW (2010) CGRP receptor antagonism and migraine. Neurotherapeutics. 7(2):164\u2013175","journal-title":"Neurotherapeutics."},{"issue":"2","key":"1132_CR4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5214\/ans.0972.7531.12190210","volume":"19","author":"M Aggarwal","year":"2012","unstructured":"Aggarwal M, Puri V, Puri S (2012) Serotonin and CGRP in migraine. Ann Neurosci 19(2):88\u201394","journal-title":"Ann Neurosci"},{"issue":"1\u20132","key":"1132_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pain.2005.03.008","volume":"115","author":"AH Ahn","year":"2005","unstructured":"Ahn AH, Basbaum AI (2005) Where do triptans act in the treatment of migraine? Pain. 115(1\u20132):1\u20134","journal-title":"Pain."},{"issue":"1","key":"1132_CR6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/1574884712666170419155048","volume":"12","author":"AS Xavier","year":"2017","unstructured":"Xavier AS, Lakshmanan M, Gunaseelan V (2017) The journey of the non-vascular relief for migraine: from 'Triptans' to 'Ditans'. Curr Clin Pharmacol 12(1):36\u201340","journal-title":"Curr Clin Pharmacol"},{"issue":"4","key":"1132_CR7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0333102420905131","volume":"40","author":"PR Holland","year":"2020","unstructured":"Holland PR, Sureda-Gibert P, Vila-Pueyo M (2020) Rapid uptake of sumatriptan into the brain: an ongoing question of blood-brain barrier permeability. Cephalalgia. 40(4):327\u2013329","journal-title":"Cephalalgia."},{"issue":"4","key":"1132_CR8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/0333102419896370","volume":"40","author":"M Muzzi","year":"2020","unstructured":"Muzzi M, Zecchi R, Ranieri G, Urru M, Tofani L, De Cesaris F et al (2020) Ultra-rapid brain uptake of subcutaneous sumatriptan in the rat: implication for cluster headache treatment. Cephalalgia. 40(4):330\u2013336","journal-title":"Cephalalgia."},{"issue":"3","key":"1132_CR9","first-page":"935","volume":"290","author":"ML Cohen","year":"1999","unstructured":"Cohen ML, Schenck K (1999) 5-Hydroxytryptamine (1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin (1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther 290(3):935\u2013939","journal-title":"J Pharmacol Exp Ther"},{"key":"1132_CR10","unstructured":"Kovalchin J, Ghiglieri A, Zanelli E, Ings R, Mathers T (2016) Lasmiditan acts specifically on the 5-HT1F receptor in the central nervous system. Cephalalgia 36(Supplement 1):103."},{"issue":"2","key":"1132_CR11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s13311-018-0626-3","volume":"15","author":"PJ Goadsby","year":"2018","unstructured":"Goadsby PJ, Holland PR (2018) Migraine therapy: current approaches and new horizons. Neurotherapeutics. 15(2):271\u2013273","journal-title":"Neurotherapeutics."},{"issue":"5","key":"1132_CR12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","volume":"11","author":"M Farkkila","year":"2012","unstructured":"Farkkila M, Diener HC, Geraud G, Lainez M, Schoenen J, Harner N et al (2012) Efficacy and tolerability of lasmiditan, an oral 5-HT (1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 11(5):405\u2013413","journal-title":"Lancet Neurol"},{"key":"1132_CR13","doi-asserted-by":"crossref","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK et al. (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142(7):1894\u2013904.","DOI":"10.1093\/brain\/awz134"},{"issue":"Supplement 1","key":"1132_CR14","first-page":"53","volume":"130","author":"LA Wietecha","year":"2018","unstructured":"Wietecha LA, Kuca B, AsafuAdjei J, Aurora SK, Daniele MI (2018) Phase 3 studies (SAMURAI, SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine. Postgraduate Med 130(Supplement 1):53\u201354","journal-title":"Postgraduate Med"},{"issue":"Supplement 2","key":"1132_CR15","first-page":"79","volume":"25","author":"LA Wietecha","year":"2018","unstructured":"Wietecha LA, Kuca B, Case MG, Selzler KJ, Aurora SK (2018) Phase-3 study (SPARTAN) of Lasmiditan compared to placebo for acute treatment of migraine. Eur J Neurol 25(Supplement 2):79","journal-title":"Eur J Neurol"},{"key":"1132_CR16","doi-asserted-by":"crossref","unstructured":"May A, Burstein R (2019) Hypothalamic regulation of headache and migraine. Cephalalgia. 333102419867280","DOI":"10.1177\/0333102419867280"},{"key":"1132_CR17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.npep.2015.03.006","volume":"52","author":"J Tajti","year":"2015","unstructured":"Tajti J, Szok D, Majlath Z, Tuka B, Csati A, Vecsei L (2015) Migraine and neuropeptides. Neuropeptides. 52:19\u201330","journal-title":"Neuropeptides."},{"issue":"4","key":"1132_CR18","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94(4):1099\u20131142","journal-title":"Physiol Rev"},{"issue":"7","key":"1132_CR19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1046\/j.1468-2982.1997.1707785.x","volume":"17","author":"DJ Goldstein","year":"1997","unstructured":"Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT (1997) Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia. 17(7):785\u2013790","journal-title":"Cephalalgia."},{"issue":"2","key":"1132_CR20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1046\/j.1468-2982.2001.00161.x","volume":"21","author":"DJ Goldstein","year":"2001","unstructured":"Goldstein DJ, Offen WW, Klein EG, Phebus LA, Hipskind P, Johnson KW et al (2001) Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia. 21(2):102\u2013106","journal-title":"Cephalalgia."},{"key":"1132_CR21","doi-asserted-by":"publisher","unstructured":"Hoffmann J, Miller S, Martins-Oliveira M, Akerman S, Supronsinchai W, Sun H, et al (2020) PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache? Pain. https:\/\/doi.org\/10.1097\/j.pain.0000000000001858.","DOI":"10.1097\/j.pain.0000000000001858"},{"issue":"1","key":"1132_CR22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/head.12999","volume":"57","author":"SK Aurora","year":"2017","unstructured":"Aurora SK, Brin MF (2017) Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache. 57(1):109\u2013125","journal-title":"Headache."},{"issue":"2","key":"1132_CR23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2217\/pmt.15.63","volume":"6","author":"M De Felice","year":"2016","unstructured":"De Felice M, Ossipov MH (2016) Cortical and subcortical modulation of pain. Pain Manag 6(2):111\u2013120","journal-title":"Pain Manag"},{"issue":"2","key":"1132_CR24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017) Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97(2):553\u2013622","journal-title":"Physiol Rev"},{"issue":"5","key":"1132_CR25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/head.13529","volume":"59","author":"S Iyengar","year":"2019","unstructured":"Iyengar S, Johnson KW, Ossipov MH, Aurora SK (2019) CGRP and the trigeminal system in migraine. Headache. 59(5):659\u2013681","journal-title":"Headache."},{"key":"1132_CR26","first-page":"561761","volume":"2012","author":"MH Ossipov","year":"2012","unstructured":"Ossipov MH (2012) The perception and endogenous modulation of pain. Scientifica (Cairo) 2012:561761","journal-title":"Scientifica (Cairo)"},{"issue":"2","key":"1132_CR27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/SPC.0000000000000055","volume":"8","author":"MH Ossipov","year":"2014","unstructured":"Ossipov MH, Morimura K, Porreca F (2014) Descending pain modulation and chronification of pain. Curr Opin Support Palliat Care 8(2):143\u2013151","journal-title":"Curr Opin Support Palliat Care"},{"issue":"10","key":"1132_CR28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrn3057","volume":"12","author":"S Akerman","year":"2011","unstructured":"Akerman S, Holland PR, Goadsby PJ (2011) Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 12(10):570\u2013584","journal-title":"Nat Rev Neurosci"},{"issue":"Suppl 1","key":"1132_CR29","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.4103\/0972-2327.99993","volume":"15","author":"PJ Goadsby","year":"2012","unstructured":"Goadsby PJ (2012) Pathophysiology of migraine. Ann Indian Acad Neurol 15(Suppl 1):S15\u2013S22","journal-title":"Ann Indian Acad Neurol"},{"issue":"4","key":"1132_CR30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJMra010917","volume":"346","author":"PJ Goadsby","year":"2002","unstructured":"Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine--current understanding and treatment. N Engl J Med 346(4):257\u2013270","journal-title":"N Engl J Med"},{"issue":"1","key":"1132_CR31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ana.21994","volume":"68","author":"R Burstein","year":"2010","unstructured":"Burstein R, Jakubowski M, Garcia-Nicas E, Kainz V, Bajwa Z, Hargreaves R et al (2010) Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol 68(1):81\u201391","journal-title":"Ann Neurol"},{"issue":"7","key":"1132_CR32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1474-4422(09)70090-0","volume":"8","author":"J Olesen","year":"2009","unstructured":"Olesen J, Burstein R, Ashina M, Tfelt-Hansen P (2009) Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 8(7):679\u2013690","journal-title":"Lancet Neurol"},{"issue":"1","key":"1132_CR33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ana.10786","volume":"55","author":"R Burstein","year":"2004","unstructured":"Burstein R, Collins B, Jakubowski M (2004) Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 55(1):19\u201326","journal-title":"Ann Neurol"},{"issue":"2","key":"1132_CR34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ana.21211","volume":"63","author":"RB Lipton","year":"2008","unstructured":"Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML et al (2008) Cutaneous allodynia in the migraine population. Ann Neurol 63(2):148\u2013158","journal-title":"Ann Neurol"},{"issue":"1","key":"1132_CR35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ana.10785","volume":"55","author":"R Burstein","year":"2004","unstructured":"Burstein R, Jakubowski M (2004) Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 55(1):27\u201336","journal-title":"Ann Neurol"},{"issue":"Suppl 3","key":"1132_CR36","first-page":"28","volume":"15","author":"A Malick","year":"2000","unstructured":"Malick A, Burstein R (2000) Peripheral and central sensitization during migraine. Funct Neurol 15(Suppl 3):28\u201335","journal-title":"Funct Neurol"},{"issue":"40","key":"1132_CR37","doi-asserted-by":"crossref","first-page":"14204","DOI":"10.1523\/JNEUROSCI.3285-11.2011","volume":"31","author":"R Noseda","year":"2011","unstructured":"Noseda R, Jakubowski M, Kainz V, Borsook D, Burstein R (2011) Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. J Neurosci 31(40):14204\u201314217","journal-title":"J Neurosci"},{"issue":"1","key":"1132_CR38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/neu.20085","volume":"61","author":"D Borsook","year":"2004","unstructured":"Borsook D, Burstein R, Becerra L (2004) Functional imaging of the human trigeminal system: opportunities for new insights into pain processing in health and disease. J Neurobiol 61(1):107\u2013125","journal-title":"J Neurobiol"},{"issue":"9","key":"1132_CR39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0333102415613612","volume":"36","author":"M Viana","year":"2016","unstructured":"Viana M, Sances G, Ghiotto N, Guaschino E, Allena M, Nappi G et al (2016) Variability of the characteristics of a migraine attack within patients. Cephalalgia. 36(9):825\u2013830","journal-title":"Cephalalgia."},{"issue":"6","key":"1132_CR40","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.molmed.2018.04.003","volume":"24","author":"R Rua","year":"2018","unstructured":"Rua R, McGavern DB (2018) Advances in meningeal immunity. Trends Mol Med 24(6):542\u2013559","journal-title":"Trends Mol Med"},{"issue":"6","key":"1132_CR41","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/brain\/awx089","volume":"140","author":"A Hougaard","year":"2017","unstructured":"Hougaard A, Amin FM, Christensen CE, Younis S, Wolfram F, Cramer SP et al (2017) Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain. 140(6):1633\u20131642","journal-title":"Brain."},{"issue":"Pt 7","key":"1132_CR42","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/brain\/aww096","volume":"139","author":"CJ Schankin","year":"2016","unstructured":"Schankin CJ, Maniyar FH, Seo Y, Kori S, Eller M, Chou DE et al (2016) Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain. 139(Pt 7):1994\u20132001","journal-title":"Brain."},{"issue":"3","key":"1132_CR43","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2567.2007.02705.x","volume":"123","author":"M Kulka","year":"2008","unstructured":"Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP (2008) Neuropeptides activate human mast cell degranulation and chemokine production. Immunology. 123(3):398\u2013410","journal-title":"Immunology."},{"issue":"4","key":"1132_CR44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/head.13053","volume":"57","author":"HG Sutherland","year":"2017","unstructured":"Sutherland HG, Griffiths LR (2017) Genetics of migraine: insights into the molecular basis of migraine disorders. Headache. 57(4):537\u2013569","journal-title":"Headache."},{"issue":"21","key":"1132_CR45","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1212\/WNL.0000000000003963","volume":"88","author":"LH Schulte","year":"2017","unstructured":"Schulte LH, Allers A, May A (2017) Hypothalamus as a mediator of chronic migraine: evidence from high-resolution fMRI. Neurology. 88(21):2011\u20132016","journal-title":"Neurology."},{"issue":"Pt 1","key":"1132_CR46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/brain\/awt320","volume":"137","author":"FH Maniyar","year":"2014","unstructured":"Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ (2014) Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 137(Pt 1):232\u2013241","journal-title":"Brain."},{"issue":"Pt 7","key":"1132_CR47","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/brain\/aww097","volume":"139","author":"LH Schulte","year":"2016","unstructured":"Schulte LH, May A (2016) The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain. 139(Pt 7):1987\u20131993","journal-title":"Brain."},{"issue":"Suppl 1","key":"1132_CR48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10072-017-2866-0","volume":"38","author":"A May","year":"2017","unstructured":"May A (2017) Understanding migraine as a cycling brain syndrome: reviewing the evidence from functional imaging. Neurol Sci 38(Suppl 1):125\u2013130","journal-title":"Neurol Sci"},{"issue":"4","key":"1132_CR49","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0306-4522(98)00536-3","volume":"90","author":"RJ Storer","year":"1999","unstructured":"Storer RJ, Goadsby PJ (1999) Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience. 90(4):1371\u20131376","journal-title":"Neuroscience."},{"key":"1132_CR50","first-page":"9","volume":"31","author":"RJ Storer","year":"2011","unstructured":"Storer RJ, Goadsby PJ (2011) 5-ht1F agonists inhibit nociceptive transmission at the trigeminocervical complex. Cephalalgia. 31:9\u201310","journal-title":"Cephalalgia."},{"key":"1132_CR51","doi-asserted-by":"crossref","unstructured":"Tso AR, Goadsby PJ (2014) New Targets for Migraine Therapy. Curr Treat Options Neurol 16(11):318.","DOI":"10.1007\/s11940-014-0318-1"},{"issue":"8","key":"1132_CR52","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1046\/j.1468-2982.2003.00525.x","volume":"23","author":"NM Ramadan","year":"2003","unstructured":"Ramadan NM, Skljarevski V, Phebus LA, Johnson KW (2003) 5-HT1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia. 23(8):776\u2013785","journal-title":"Cephalalgia."},{"issue":"3","key":"1132_CR53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-020-01264-5","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ (2020) Ubrogepant: first approval. Drugs. 80(3):323\u2013328","journal-title":"Drugs."},{"key":"1132_CR54","unstructured":"Biohaven Pharmaceuticals I. Rimegepant: highlights of prescribing information. New Haven, CT2020"},{"issue":"2","key":"1132_CR55","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1124\/jpet.113.206458","volume":"347","author":"ED Hostetler","year":"2013","unstructured":"Hostetler ED, Joshi AD, Sanabria-Bohorquez S, Fan H, Zeng Z, Purcell M et al (2013) In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther 347(2):478\u2013486","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1132_CR56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1227\/01.NEU.0000097715.11966.8E","volume":"54","author":"EA Neuwelt","year":"2004","unstructured":"Neuwelt EA (2004) Mechanisms of disease: the blood-brain barrier. Neurosurgery. 54(1):131\u2013140 discussion 41-2","journal-title":"Neurosurgery."},{"issue":"10","key":"1132_CR57","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/0333102419844711","volume":"39","author":"KW Johnson","year":"2019","unstructured":"Johnson KW, Morin SM, Wroblewski VJ, Johnson MP (2019) Peripheral and central nervous system distribution of the CGRP neutralizing antibody [(125) I] galcanezumab in male rats. Cephalalgia. 39(10):1241\u20131248","journal-title":"Cephalalgia."},{"issue":"24","key":"1132_CR58","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/BF01466734","volume":"52","author":"K Felgenhauer","year":"1974","unstructured":"Felgenhauer K (1974) Protein size and cerebrospinal fluid composition. Klin Wochenschr 52(24):1158\u20131164","journal-title":"Klin Wochenschr"},{"issue":"4","key":"1132_CR59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","volume":"158","author":"S Iyengar","year":"2017","unstructured":"Iyengar S, Ossipov MH, Johnson KW (2017) The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 158(4):543\u2013559","journal-title":"Pain."},{"issue":"2","key":"1132_CR60","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1073\/pnas.90.2.408","volume":"90","author":"N Adham","year":"1993","unstructured":"Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D et al (1993) Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A 90(2):408\u2013412","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1132_CR61","first-page":"219","volume":"50","author":"I Bouchelet","year":"1996","unstructured":"Bouchelet I, Cohen Z, Case B, Seguela P, Hamel E (1996) Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 50(2):219\u2013223","journal-title":"Mol Pharmacol"},{"issue":"9\u201310","key":"1132_CR62","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1097\/00001756-199707070-00029","volume":"8","author":"KW Johnson","year":"1997","unstructured":"Johnson KW, Schaus JM, Durkin MM, Audia JE, Kaldor SW, Flaugh ME et al (1997) 5-HT1F receptor agonists inhibit neurogenic dural inflammation in Guinea pigs. Neuroreport. 8(9\u201310):2237\u20132240","journal-title":"Neuroreport."},{"key":"1132_CR63","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fneur.2016.00173","volume":"7","author":"HO Usman","year":"2016","unstructured":"Usman HO, Balaban CD (2016) Distribution of 5-HT1F receptors in monkey vestibular and trigeminal ganglion cells. Front Neurol 7:173","journal-title":"Front Neurol"},{"issue":"4","key":"1132_CR64","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.pain.2012.01.005","volume":"153","author":"DV Amrutkar","year":"2012","unstructured":"Amrutkar DV, Ploug KB, Hay-Schmidt A, Porreca F, Olesen J, Jansen-Olesen I (2012) mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain. 153(4):830\u2013838","journal-title":"Pain."},{"issue":"1\u20132","key":"1132_CR65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(01)01605-3","volume":"436","author":"P Bhalla","year":"2002","unstructured":"Bhalla P, Sharma HS, Wurch T, Pauwels PJ, Saxena PR (2002) Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht (1F) receptor. Eur J Pharmacol 436(1\u20132):23\u201333","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"1132_CR66","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/00004647-199908000-00010","volume":"19","author":"Z Cohen","year":"1999","unstructured":"Cohen Z, Bouchelet I, Olivier A, Villemure JG, Ball R, Stanimirovic DB et al (1999) Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. J Cereb Blood Flow Metab 19(8):908\u2013917","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3\u20134","key":"1132_CR67","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0028-3908(94)90067-1","volume":"33","author":"AT Bruinvels","year":"1994","unstructured":"Bruinvels AT, Landwehrmeyer B, Gustafson EL, Durkin MM, Mengod G, Branchek TA et al (1994) Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology. 33(3\u20134):367\u2013386","journal-title":"Neuropharmacology."},{"issue":"4\u20135","key":"1132_CR68","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0028-3908(97)00061-0","volume":"36","author":"ME Castro","year":"1997","unstructured":"Castro ME, Pascual J, Romon T, del Arco C, del Olmo E, Pazos A (1997) Differential distribution of [3H] sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brainstem and spinal cord. Neuropharmacology. 36(4\u20135):535\u2013542","journal-title":"Neuropharmacology."},{"issue":"1\u20133","key":"1132_CR69","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0014-2999(95)00275-P","volume":"283","author":"C Waeber","year":"1995","unstructured":"Waeber C, Moskowitz MA (1995) Autoradiographic visualisation of [3H]5-carboxamidotryptamine binding sites in the Guinea pig and rat brain. Eur J Pharmacol 283(1\u20133):31\u201346","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1132_CR70","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00168556","volume":"352","author":"C Waeber","year":"1995","unstructured":"Waeber C, Moskowitz MA (1995) [3H] sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the Guinea pig brain: an autoradiographic study. Naunyn Schmiedeberg's Arch Pharmacol 352(3):263\u2013275","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"2\u20133","key":"1132_CR71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0014-2999(95)00748-2","volume":"295","author":"J Pascual","year":"1996","unstructured":"Pascual J, Del Arco C, Romon T, Del Olmo E, Pazos A (1996) [3H] Sumatriptan binding sites in human brain: regional-dependent labelling of 5-HT1D and 5-HT1F receptors. Eur J Pharmacol 295(2\u20133):271\u2013274","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1132_CR72","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00210-005-1036-8","volume":"371","author":"VL Lucaites","year":"2005","unstructured":"Lucaites VL, Krushinski JH, Schaus JM, Audia JE, Nelson DL (2005) [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, Guinea pig, monkey and human brain. Naunyn Schmiedeberg's Arch Pharmacol 371(3):178\u2013184","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"1132_CR73","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.brainres.2010.09.004","volume":"1361","author":"JD Classey","year":"2010","unstructured":"Classey JD, Bartsch T, Goadsby PJ (2010) Distribution of 5-HT (1B), 5-HT (1D) and 5-HT (1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans. Brain Res 1361:76\u201385","journal-title":"Brain Res"},{"key":"1132_CR74","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","volume":"186","author":"E Rubio-Beltran","year":"2018","unstructured":"Rubio-Beltran E, Labastida-Ramirez A, Villalon CM, MaassenVanDenBrink A (2018) Is selective 5-HT<inf>1F<\/inf> receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther 186:88\u201397","journal-title":"Pharmacol Ther"},{"issue":"2","key":"1132_CR75","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s13311-018-0615-6","volume":"15","author":"M Vila-Pueyo","year":"2018","unstructured":"Vila-Pueyo M (2018) Targeted 5-HT1F therapies for migraine. Neurotherapeutics. 15(2):291\u2013303","journal-title":"Neurotherapeutics."},{"issue":"Supplement 1","key":"1132_CR76","first-page":"152","volume":"36","author":"M Vila-Pueyo","year":"2016","unstructured":"Vila-Pueyo M, Strother L, Page K, Loaraine H, Kovalchin J, Goadsby PJ et al (2016) Lasmiditan inhibits trigeminovascular nociceptive transmission. Cephalalgia 36(Supplement 1):152\u2013153","journal-title":"Cephalalgia"},{"issue":"6","key":"1132_CR77","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40263-019-00630-6","volume":"33","author":"KA Haanes","year":"2019","unstructured":"Haanes KA, Edvinsson L (2019) Pathophysiological mechanisms in migraine and the identification of new therapeutic targets. CNS Drugs 33(6):525\u2013537","journal-title":"CNS Drugs"},{"key":"1132_CR78","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-physiol-030212-183717","volume":"75","author":"D Pietrobon","year":"2013","unstructured":"Pietrobon D, Moskowitz MA (2013) Pathophysiology of migraine. Annu Rev Physiol 75:365\u2013391","journal-title":"Annu Rev Physiol"},{"issue":"8","key":"1132_CR79","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/00001756-200106130-00015","volume":"12","author":"QP Ma","year":"2001","unstructured":"Ma QP (2001) Co-localization of 5-HT (1B\/1D\/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport. 12(8):1589\u20131591","journal-title":"Neuroreport."},{"issue":"2","key":"1132_CR80","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/WNR.0b013e328320795e","volume":"20","author":"SK Ahn","year":"2009","unstructured":"Ahn SK, Khalmuratova R, Jeon SY, Kim JP, Park JJ, Hur DG et al (2009) Colocalization of 5-HT1F receptor and glutamate in neurons of the vestibular nuclei in rats. Neuroreport. 20(2):111\u2013115","journal-title":"Neuroreport."},{"issue":"2","key":"1132_CR81","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neulet.2009.09.008","volume":"465","author":"SK Ahn","year":"2009","unstructured":"Ahn SK, Khalmuratova R, Jeon SY, Kim JP, Park JJ, Hur DG et al (2009) Colocalization of 5-HT1F receptor and calcitonin gene-related peptide in rat vestibular nuclei. Neurosci Lett 465(2):151\u2013156","journal-title":"Neurosci Lett"},{"issue":"8","key":"1132_CR82","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","volume":"12","author":"A May","year":"2016","unstructured":"May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12(8):455\u2013464","journal-title":"Nat Rev Neurol"},{"key":"1132_CR83","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fneur.2018.00061","volume":"9","author":"L Solstrand Dahlberg","year":"2018","unstructured":"Solstrand Dahlberg L, Linnman CN, Lee D, Burstein R, Becerra L, Borsook D (2018) Responsivity of periaqueductal gray connectivity is related to headache frequency in episodic migraine. Front Neurol 9:61","journal-title":"Front Neurol"},{"issue":"8","key":"1132_CR84","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1526-4610.1987.hed2708416.x","volume":"27","author":"NH Raskin","year":"1987","unstructured":"Raskin NH, Hosobuchi Y, Lamb S (1987) Headache may arise from perturbation of brain. Headache. 27(8):416\u2013420","journal-title":"Headache."},{"issue":"3","key":"1132_CR85","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ana.20193","volume":"56","author":"T Bartsch","year":"2004","unstructured":"Bartsch T, Knight YE, Goadsby PJ (2004) Activation of 5-HT (1B\/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 56(3):371\u2013381","journal-title":"Ann Neurol"},{"issue":"1","key":"1132_CR86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-010-0105-6","volume":"13","author":"TS Monteith","year":"2011","unstructured":"Monteith TS, Goadsby PJ (2011) Acute migraine therapy: new drugs and new approaches. Curr Treat Options Neurol 13(1):1\u201314","journal-title":"Curr Treat Options Neurol"},{"issue":"21","key":"1132_CR87","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0024-3205(97)00885-0","volume":"61","author":"LA Phebus","year":"1997","unstructured":"Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V et al (1997) Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 61(21):2117\u20132126","journal-title":"Life Sci"},{"issue":"3","key":"1132_CR88","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0014-2999(99)00067-9","volume":"369","author":"DD Mitsikostas","year":"1999","unstructured":"Mitsikostas DD (1999) Sanchez del Rio M, Moskowitz MA, Waeber C. both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur J Pharmacol 369(3):271\u2013277","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1132_CR89","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00210-005-1035-9","volume":"371","author":"DB Wainscott","year":"2005","unstructured":"Wainscott DB, Krushinski JH Jr, Audia JE, Schaus JM, Zgombick JM, Lucaites VL et al (2005) [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. in vitro characterization of binding properties. Naunyn Schmiedeberg's Arch Pharmacol 371(3):169\u2013177","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"1","key":"1132_CR90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-2999(98)00336-7","volume":"352","author":"DB Wainscott","year":"1998","unstructured":"Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL (1998) Human 5-HT1F receptor-stimulated [35S] GTPgammaS binding: correlation with inhibition of Guinea pig dural plasma protein extravasation. Eur J Pharmacol 352(1):117\u2013124","journal-title":"Eur J Pharmacol"},{"issue":"9289","key":"1132_CR91","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(01)06347-4","volume":"358","author":"DJ Goldstein","year":"2001","unstructured":"Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW et al (2001) Selective seratonin 1F (5-HT (1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 358(9289):1230\u20131234","journal-title":"Lancet."},{"issue":"10","key":"1132_CR92","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","volume":"30","author":"DL Nelson","year":"2010","unstructured":"Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO et al (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 30(10):1159\u20131169","journal-title":"Cephalalgia."},{"key":"1132_CR93","unstructured":"Eli Lilly and Company. REYVOW medication guide. 2019"},{"issue":"24","key":"1132_CR94","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1111\/bph.14832","volume":"176","author":"E Rubio-Beltran","year":"2019","unstructured":"Rubio-Beltran E, Labastida-Ramirez A, Haanes KA, van den Bogaerdt A, Bogers A, Zanelli E et al (2019) Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan. Br J Pharmacol 176(24):4681\u20134695","journal-title":"Br J Pharmacol"},{"issue":"6","key":"1132_CR95","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1468-2982.1997.1706631.x","volume":"17","author":"ML Cohen","year":"1997","unstructured":"Cohen ML, Johnson KW, Schenck KW, Phebus LA (1997) Migraine therapy: relationship between serotonergic contractile receptors in canine and rabbit saphenous veins to human cerebral and coronary arteries. Cephalalgia. 17(6):631\u2013638","journal-title":"Cephalalgia."},{"issue":"5","key":"1132_CR96","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","volume":"161","author":"A Labastida-Ramirez","year":"2020","unstructured":"Labastida-Ramirez A, Rubio-Beltran E, Haanes KA, Chan KY, Garrelds IM, Johnson KW et al (2020) Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain. 161(5):1092\u20131099","journal-title":"Pain."},{"issue":"3","key":"1132_CR97","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.bjp.0702584","volume":"127","author":"DD Mitsikostas","year":"1999","unstructured":"Mitsikostas DD, Sanchez del Rio M, Waeber C, Huang Z, Cutrer FM, Moskowitz MA (1999) Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol 127(3):623\u2013630","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1132_CR98","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s13311-018-0616-5","volume":"15","author":"J Hoffmann","year":"2018","unstructured":"Hoffmann J, Charles A (2018) Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics. 15(2):361\u2013370","journal-title":"Neurotherapeutics."},{"issue":"10","key":"1132_CR99","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/0333102410375512","volume":"30","author":"MD Ferrari","year":"2010","unstructured":"Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauss M et al (2010) Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial. Cephalalgia. 30(10):1170\u20131178","journal-title":"Cephalalgia."},{"issue":"24","key":"1132_CR100","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB et al (2018) Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 91(24):e2222\u2013e2e32","journal-title":"Neurology."},{"issue":"1","key":"1132_CR101","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","volume":"20","author":"RE Shapiro","year":"2019","unstructured":"Shapiro RE, Hochstetler HM, Dennehy EB, Khanna R, Doty EG, Berg PH et al (2019) Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain. 20(1):90","journal-title":"J Headache Pain."},{"key":"1132_CR102","doi-asserted-by":"crossref","unstructured":"Kudrow D, Krege J, Hundemer HP, Berg PH, Khanna R, Ossipov MH, et al. Issues impacting adverse event frequency and severity: Differences between randomized phase 2 and phase 3 clinical trials for lasmiditan. Headache. 2019;in press","DOI":"10.1111\/head.13731"},{"issue":"8","key":"1132_CR103","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0333102419855080","volume":"39","author":"JH Krege","year":"2019","unstructured":"Krege JH, Rizzoli PB, Liffick E, Doty EG, Dowsett SA, Wang J et al (2019) Safety findings from phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. Cephalalgia. 39(8):957\u2013966","journal-title":"Cephalalgia."},{"issue":"1","key":"1132_CR104","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10194-010-0250-z","volume":"12","author":"JM Furman","year":"2011","unstructured":"Furman JM, Marcus DA, Balaban CD (2011) Rizatriptan reduces vestibular-induced motion sickness in migraineurs. J Headache Pain. 12(1):81\u201388","journal-title":"J Headache Pain."},{"issue":"7","key":"1132_CR105","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1474-4422(13)70107-8","volume":"12","author":"JM Furman","year":"2013","unstructured":"Furman JM, Marcus DA, Balaban CD (2013) Vestibular migraine: clinical aspects and pathophysiology. Lancet Neurol 12(7):706\u2013715","journal-title":"Lancet Neurol"},{"issue":"11","key":"1132_CR106","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1468-2982.2006.01208.x","volume":"26","author":"JW Koo","year":"2006","unstructured":"Koo JW, Balaban CD (2006) Serotonin-induced plasma extravasation in the murine inner ear: possible mechanism of migraine-associated inner ear dysfunction. Cephalalgia. 26(11):1310\u20131319","journal-title":"Cephalalgia."},{"issue":"10","key":"1132_CR107","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1517\/13543784.10.10.1831","volume":"10","author":"HC Diener","year":"2001","unstructured":"Diener HC, Limmroth V (2001) Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 10(10):1831\u20131845","journal-title":"Expert Opin Investig Drugs"},{"key":"1132_CR108","doi-asserted-by":"crossref","unstructured":"Knievel K, Buchanan AS, Lombard L, Baygani S, Raskin J, Krege JH et al (2019) Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia. 333102419889350","DOI":"10.1177\/0333102419889350"},{"issue":"3","key":"1132_CR109","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.102.039255","volume":"303","author":"KM Mahar Doan","year":"2002","unstructured":"Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ et al (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303(3):1029\u20131037","journal-title":"J Pharmacol Exp Ther"},{"key":"1132_CR110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1526-4610.2005.05003.x","volume":"45","author":"J Pascual","year":"2005","unstructured":"Pascual J, Munoz P (2005) Correlation between Lipophilicity and Triptan outcomes. Headache. 45:3\u20136","journal-title":"Headache."},{"issue":"7","key":"1132_CR111","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1124\/dmd.31.7.861","volume":"31","author":"DC Evans","year":"2003","unstructured":"Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R (2003) Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 31(7):861\u2013869","journal-title":"Drug Metab Dispos"},{"issue":"13","key":"1132_CR112","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1080\/14656566.2017.1361406","volume":"18","author":"B Raffaelli","year":"2017","unstructured":"Raffaelli B, Israel H, Neeb L, Reuter U (2017) The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opin Pharmacother 18(13):1409\u20131415","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1132_CR113","doi-asserted-by":"crossref","first-page":"944","DOI":"10.5114\/aoms.2019.86061","volume":"15","author":"M Fila","year":"2019","unstructured":"Fila M, Pawlowska E, Blasiak J (2019) Mitochondria in migraine pathophysiology - does epigenetics play a role? Arch Med Sci 15(4):944\u2013956","journal-title":"Arch Med Sci"},{"issue":"4","key":"1132_CR114","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0361-9230(01)00440-3","volume":"54","author":"R Lodi","year":"2001","unstructured":"Lodi R, Iotti S, Cortelli P, Pierangeli G, Cevoli S, Clementi V et al (2001) Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res Bull 54(4):437\u2013441","journal-title":"Brain Res Bull"},{"issue":"4","key":"1132_CR115","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1468-2982.2005.01059.x","volume":"26","author":"M Sparaco","year":"2006","unstructured":"Sparaco M, Feleppa M, Lipton RB, Rapoport AM, Bigal ME (2006) Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia. 26(4):361\u2013372","journal-title":"Cephalalgia."},{"key":"1132_CR116","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s10194-015-0516-6","volume":"16","author":"C Gaul","year":"2015","unstructured":"Gaul C, Diener HC, Danesch U, Migravent SG (2015) Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 16:516","journal-title":"J Headache Pain"},{"issue":"2","key":"1132_CR117","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1124\/jpet.114.214700","volume":"350","author":"SM Garrett","year":"2014","unstructured":"Garrett SM, Whitaker RM, Beeson CC, Schnellmann RG (2014) Agonism of the 5-hydroxytryptamine 1F receptor promotes mitochondrial biogenesis and recovery from acute kidney injury. J Pharmacol Exp Ther 350(2):257\u2013264","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1132_CR118","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bph.14076","volume":"175","author":"NE Scholpa","year":"2018","unstructured":"Scholpa NE, Lynn MK, Corum D, Boger HA, Schnellmann RG (2018) 5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson's disease. Br J Pharmacol 175(2):348\u2013358","journal-title":"Br J Pharmacol"},{"key":"1132_CR119","doi-asserted-by":"crossref","first-page":"113644","DOI":"10.1016\/j.bcp.2019.113644","volume":"169","author":"TV Dupre","year":"2019","unstructured":"Dupre TV, Jenkins DP, Muise-Helmericks RC, Schnellmann RG (2019) The 5-hydroxytryptamine receptor 1F stimulates mitochondrial biogenesis and angiogenesis in endothelial cells. Biochem Pharmacol 169:113644","journal-title":"Biochem Pharmacol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01132-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-020-01132-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01132-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T23:05:49Z","timestamp":1623279949000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01132-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01132-3","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"David B. Clemow, Kirk W. Johnson, Helen M. Hochstetler, and Ann M. Hake are employed by and are stockholders of Eli Lilly and Company. Michael H. Ossipov is employed by Evidera and owns some Lilly stock. Andrew M. Blumenfeld has received fees for consulting and promotional speaking from Eli Lilly and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}